Popular Articles

SYNTAX Substudy Shows Positive Outcomes For Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
Boston Scientific Corporation (NYSE: BSX) announced positive outcomes from a substudy of patients with left main coronary disease who were treated with the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System. SYNTAX-LE MANS is a substudy of the landmark SYNTAX trial, the first randomized, controlled clinical trial to compare percutaneous coronary intervention (PCI) using the TAXUS Stent to coronary artery bypass graft (CABG) surgery in patients with left main disease and/or significant narrowing of all three coronary arteries (three-vessel disease). The substudy data were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual EuroPCR Scientific Program in Barcelona.

Infection Control 'Urgently Needed' To Curb Spread Of XDR-TB Among Health Care Workers
Healthcare workers in South Africa are at a significantly increased risk of developing drug-resistant tuberculosis, or XDR-TB, in a trend which threatens to further exacerbate the already beleaguered healthcare systems in sub-Saharan countries, according to results of a new study. Researchers say the results underscore the urgent need for stringent TB screening policies among healthcare workers in these areas.
News of the day
Ablynx Announces A Novel Preclinical Development Candidate Targeting IL6R
Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases.
Mental Health

National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support

The American Society of Interventional Pain Physicians (ASIPP) announced that the National All Schedules Prescription Electronic Reporting (NASPER) Act has received the support of Senator John D. Rockefeller IV of West Virginia and Senator Bob Corker of Tennessee. NASPER was unanimously passed by both the House and the Senate and signed into law on August 11, 2005 by President George W. Bush, and received preliminary funding of $2 million for the Fiscal Year 2009 and 2010. Proposed by ASIPP, with the support of the American Medical Association, the American Society of Anesthesiologists and other organizations, NASPER"s purpose is to provide and improve patient access to quality care. It was also created to protect patients and physicians from the deleterious effects of controlled substance misuse, abuse and trafficking. The ultimate goal of NASPER is to have a coordinated prescription monitoring program in all 50 states, which could save hundreds of millions of dollars in prescriptions in the Medicaid and Medicare programs. "While the preliminary funding of NASPER is a promising start, it is imperative to secure full funding in order to realize its full potential and possibly save countless numbers of lives," said Dr. Laxmaiah Manchikanti, ASIPP CEO and Chairman of the Board. "The abuse of prescription drugs continues to be a problem that plagues millions of Americans and their families every day," said Rep. Ed Whitfield who first authored the legislation in the 108th Congress. "NASPER is a powerful weapon in the fight against prescription drug abuse that will allow physicians to detect abuse and prevent the practice of doctor shopping across state lines. I am pleased that NASPER has, at long last, received the funding that it needs to be implemented and start saving lives." According to the National Institute of Drug Abuse, abuse of prescription medications is on the rise. Prescription drug monitoring programs are an important tool to help and track illegal activity related to the prescription of these drugs. Senators Rockefeller and Corker have stated that NASPER is a "vital tool for states to combat substance abuse," and urge the Appropriations Committee to provide $25 million for the 2010 Fiscal Year. Currently, there are 38 states that individually fund their own prescription monitoring programs based on requirements originally set by NASPER. With additional appropriated support, states will have the res necessary to enhance their programs and meet statutorily defined requirements. "NASPER has made strides since its inception in 2005, but the endorsement of Senator Rockefeller and Senator Corker will hopefully move NASPER into the next crucial phase," said Dr. Manchikanti. "We are so grateful for the support from the senators and those who have shown dedication over the years, especially the tireless efforts of Rep. Ed Whitfield, Rep. Bart Stupak, Sen. Jeff Sessions, and Sen. Richard Durbin." About The American Society of Interventional Pain Physicians ASIPP"s mission statement is to promote the development and practice of safe, high quality, cost-effective interventional pain management techniques for the diagnosis and treatment of pain and related disorders, and to ensure patient access to these interventions. Founded in 1998 by current CEO Laxmaiah Manchikanti, MD, ASIPP is a rapidly growing not-for-profit organization that supports the needs of physicians who practice Interventional Pain Management across the country. Since its inception, the organization has had substantial impact on the practice of interventional pain medicine, resulting in an impressive list of major achievements. In 2005, ASIPP succeeded in passing The National All Schedules Prescription Electronic Reporting Act (NASPER), which provides and improves patient access to quality care, and protects patients and physicians from the deleterious effects of controlled substance misuse, abuse and trafficking. ASIPP is headquartered in Paducah, KY and currently has over 5,000 members. The American Society of Interventional Pain Physicians


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):